Innova Captab Ltd - Q1 FY27 Earnings Call Summary Wednesday, August 12, 2026 11:00 AM IST
Event Participants
Executives
2 Lokesh Bhasin, Vinay Kumar Lohariwala
Analysts
11 Aanchal Maheshwari, Amrita Maloo, Ankit Shah, Deepak Ajmera, Juhi Kumari, Nitish Rege, Pavithra Jaivant, Pritesh Chheda, Siddhant Mantri, Vansh Gupta, Vedant Nilekar
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹470.9 crores | Strong 34% YoY growth, supported by demand across both CDMO and Branded Generics businesses |
| CDMO Revenue | ₹328.7 crores | 32% YoY growth, driven by expanding product portfolio, new customer additions and higher wallet share from existing customers |
| Branded Generics Revenue | ₹142.2 crores | 39% YoY growth, supported by continued traction across key markets |
| EBITDA | ₹75.1 crores | 33% YoY growth; margin at 16.0% |
| PAT | ₹44.1 crores | 42% YoY growth, outpacing revenue growth |
| Gross Margin | 35.5% | Down ~1-1.5% YoY due to business mix; guided to stay within ±2% for full year |
| Exports Share | 32% of revenue | Continued progress in international market expansion; domestic ~70%, exports ~30% |
| Volume Growth | 20-22% YoY | At overall manufacturing capability level; ex-Jammu volume growth ~12-14% |
| Jammu Facility Revenue | ₹107 crores | Up from ~₹90 crores in Q4 FY26; annualized capacity utilization ~25-30% |
| Jammu EBITDA | ₹1-1.5 crores | Positive EBITDA achieved for first time; offsetting drag from ramp-up |
| Cash Conversion Cycle | ~90 days ±10 days | Normalized after Jammu initial working capital build-up in previous year |
| R&D Spend | 0.7-1% of revenue | Continuous product development pipeline with firm timelines across short, mid and long term |
Geographic & Segment Commentary
CDMO Business: Revenue of ₹328.7 crores, growing 32% YoY. Growth driven by steady order flows, new customer additions across therapeutic categories and dosage forms, and deeper engagement with existing customers yielding higher wallet share. Strategy focused on complex dosage capabilities, formulation development, and automation to strengthen competitive positioning.
Branded Generics Business: Revenue of ₹142.2 crores, growing 39% YoY. Strategy centered on strengthening presence in existing markets while gradually expanding into newer domestic and international geographies. Integrated manufacturing and product development capabilities support medium-to-long-term diversification of revenue base.
Jammu Facility: Commenced ramp-up with quarterly revenue of ₹107 crores (vs ~₹90 crores prior quarter) at 25-30% annualized utilization. Positive EBITDA of ₹1-1.5 crores achieved this quarter. Management expects asset turns north of 3x at optimum level and peak revenue potential of ₹1,400 crores at 65-70% utilization, with ramp-up accelerating from Q2 onwards as seasonal demand picks up.
Company-Specific & Strategic Commentary
Dual Business Model (CDMO + Branded Generics): Branded Generics operates as a normal CDMO customer at plant level with arm's-length product transfers; management sees no conflict of interest, citing industry-accepted practice of combined business models.
Growth Engine Strategy: Two-pronged approach - expanding existing saturated categories (tablets, capsules, oral liquids) and entering new dosage forms/therapeutic categories. Company present in 6-7 categories with room to extend. This supports sustainable 20%+ CAGR ambition.
Advanced Capabilities: Jammu facility PIC/S approved, focused on penem, beta-lactam, and cephalosporin categories with 2-3 years of capacity headroom. Witnessing good progress on new product approvals from ROW markets expected by end of FY27.
Semaglutide Development: Product development ongoing, status unchanged from last quarter; plant team actively working on batches.
Future Capex Plans: Baddi new plot (acquired last year) - plan being finalized, concrete proposal to be shared with market once formed. Fresh investments in existing categories and debottlenecking are in progress.
Subsidiary Sharon: Seasonal impact in Q1; full-year expectation of high-teens growth consistent with organic business run-rate.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | 20%+ (volume basis) | Maintained after Q1 beat (34% actual); volume growth guided at 20%+ YoY with price held constant; Q1 volume growth of ~22% provides confidence |
| Profitability vs Revenue | Outpace revenue | PAT growth of 42% in Q1 vs revenue growth of 34%; management reaffirms earnings growth exceeding revenue |
| EBITDA Margin | 15-16% ±2% | Blended margin profile across business areas and geographies; gross margin expected at 35.5% ±2% |
| Margin Trajectory | Expand to 17-18% | Once Jammu reaches contributing margin, overall consolidated margin could expand 2-3% from current levels; normalized ex-Jammu margin viewed at 17-18%, not 20% |
| Annual Maintenance CapEx | ₹20-25 crores | Normal course of business for replacement of aged assets |
| Annual Growth CapEx | ₹20-30 crores | For existing capability augmentation and debottlenecking within current facilities; larger greenfield capex to be announced separately |
| Jammu Optimum Utilization | ₹1,400 crores revenue | Expected at 65-70% utilization with asset turns north of 3x; ramp-up timeline dependent on customer on-boarding, country audits, and regulatory approvals through FY27 |
| Working Capital | ~90 days ±10 days | Normalized post-Jammu ramp-up; initial working capital build-up already absorbed in prior year |
Risks & Constraints
| Risk | Context |
|---|---|
| Jammu Ramp-up Execution | Plant at 25-30% utilization with ₹107 crores quarterly revenue; management acknowledges "challenges always will be there" - customer on-boarding, country audits, and regulatory approvals may take time. Positive EBITDA of ₹1-1.5 crores achieved, but margin drag continues until utilization escalates. |
| Business Mix & Margin Volatility | Gross margin down ~1-1.5% YoY due to product/sales mix changes. Management guides 15-16% ±2% EBITDA margin, acknowledging quarter-to-quarter volatility from market conditions and seasonal factors across business areas and geographies. |
| API Price Fluctuations | Pass-through model protects against major impact, but management noted API prices influenced towards increasing during Q1. Timing mismatches (inventory holding vs confirmed sales orders) can create short-term positive or negative margin effects. |
| Geopolitical / Macro Factors | Management cited "macro-political and geopolitical reasons" as variables affecting business mix and revenue; CFO noted minor increase in logistics costs from global supply chain disruption, factored into overall revenue scenario. |
| Capacity Constraints in Core Categories | Existing Baddi portfolio categories (tablets, capsules, oral liquids) approaching saturation; further volumes require expansion in these categories or entry into new therapeutic/dosage areas, necessitating additional capex. |
Q&A Highlights
Jammu Ramp-up, Revenues, and Asset Turns
- Question: What is the quarterly revenue from Jammu, and what asset turns should we expect? (Deepak Ajmera)
- Answer: Jammu revenue was ₹107 crores in Q1 FY27 versus ~₹90 crores in Q4 FY26. Ramp-up is pacing as expected, with Q2 onwards historically being a stronger season. At optimum utilization, asset turn expected north of 3x. (Lokesh Bhasin)
- Question: What is current capacity utilization? (Aanchal Maheshwari)
- Answer: 25-30% utilization on an annualized basis based on Q1 performance. (Lokesh Bhasin)
- Question: What is Jammu peak revenue potential? (Amrita Maloo)
- Answer: ₹1,400 crores at 65-70% utilization, inclusive of government incentives. (Vinay Kumar Lohariwala)
- Question: What visibility do you have on reaching optimum utilization? (Siddhant Mantri)
- Answer: PIC/S approval received last year; ROW country product approvals expected by end of FY27; onboarding of marquee domestic customers and product registrations driving the ramp-up path. (Vinay Kumar Lohariwala)
Working Capital Normalization
- Question: Has the cash conversion cycle returned to historical levels post-Jammu ramp-up? (Juhi Kumari)
- Answer: Yes - initial working capital build-up for Jammu was absorbed in the previous year. Maintaining expected cash conversion cycle of 90 days ±10 days at group level. (Lokesh Bhasin)
Gross Margin Trend and Business Mix
- Question: Gross margin dipped YoY - what's the outlook? (Vedant Nilekar)
- Answer: Decline of ~1-1.5% YoY is normal course, mainly due to business mix contribution. On a full-year basis, expect gross margin to maintain 35.5% ±2%. (Lokesh Bhasin)
Growth Decomposition (Volume vs Price/Mix)
- Question: Can you break the 34% revenue growth between volume and realization, and ex-Jammu volume growth? (Ankit Shah)
- Answer: Volume growth at ~20-22% at manufacturing capability level; balance from favorable product/sales mix and pricing. Excluding Jammu, Baddi volume growth was ~12-14%. (Lokesh Bhasin)
Jammu Profitability and Margin Profile
- Question: Is Jammu EBITDA positive, and how should we think about consolidated margins? (Ankit Shah; Pritesh Chheda)
- Answer: Positive EBITDA of ₹1-1.5 crores achieved in Q1. Jammu margin profile will align with base business at ~17-18% once ramped. As Jammu contributes, overall margins should expand 2-3% from 16% levels. (Lokesh Bhasin; Vinay Kumar Lohariwala)
- Question: Should we expect company-level margins to move towards 18-20%? (Pritesh Chheda)
- Answer: 20% is a very high expectation; 17-18% is the fair number at blended level given future growth capex will continue to create 1-2% drag. We maintain 15-16% ±2% as normalized margin profile. (Vinay Kumar Lohariwala)
Capex Guidance and Baddi Expansion
- Question: What is annual growth and maintenance capex, and any Baddi update? (Pritesh Chheda; Ankit Shah)
- Answer: Maintenance capex ₹20-25 crores; growth capex (capability augmentation, debottlenecking) ₹20-30 crores. Baddi new plot plan is being finalized; will come to market with concrete proposal once formed up. Future greenfield projects will be announced with board approval. (Lokesh Bhasin; Vinay Kumar Lohariwala)
CDMO vs Branded Generics Conflict of Interest
- Question: Is there a conflict of interest between CDMO clients and the company's own Branded Generics business? (Pavithra Jaivant)
- Answer: No - Branded Generics is treated as a normal CDMO customer by the plants, with arm's-length product transfers. It's an open, competitive market and an accepted industry practice to have both businesses, so no conflict of interest per se. (Lokesh Bhasin)
Growth Sustainability and Capability Expansion
- Question: How much volume growth headroom exists from combined assets - is it 2-3 years? (Pritesh Chheda)
- Answer: Two engines will drive growth: (1) expanding existing categories approaching saturation (tablets, capsules, oral liquids), and (2) entering new dosage forms/therapeutic categories not currently addressed. Both support maintaining 20%+ CAGR. (Vinay Kumar Lohariwala)
Export Mix, Cost-Plus Model, and Margins
- Question: Is the 18% margin sustainable given export mix and cost-plus model? (Vansh Gupta)
- Answer: Margin profile combines complex business areas and geographies; contributions shift quarter-to-quarter based on market and seasonal conditions. We maintain blended 15-16% ±2% guidance to factor these volatilities. Ex-Jammu margins benefited from operating leverage and optimizing resources. (Lokesh Bhasin)
- Question: Did API price increases contribute to margin expansion? (Vansh Gupta)
- Answer: API is generally pass-through; occasional positive/negative impact from inventory timing, but we don't speculate on API prices. Focus remains business performance. (Vinay Kumar Lohariwala)
Subsidiary Sharon Performance
- Question: What is Sharon's YoY growth this quarter? (Vansh Gupta)
- Answer: Seasonal impact in Q1; full-year expectation of high-teens growth, consistent with organic business run-rate. The 20%+ consolidated growth comprises high-teens from base businesses plus top-up from Jammu. (Lokesh Bhasin; Vinay Kumar Lohariwala)
Semaglutide Development
- Question: Any new developments on semaglutide products? (Vansh Gupta)
- Answer: Status unchanged from last quarter; development being closely watched and plant team is working on batches. (Vinay Kumar Lohariwala)
Pricing Pressure and API Prices
- Question: Any pricing pressure on API side or products this quarter? (Siddhant Mantri)
- Answer: API prices trending upwards this quarter; under cost-plus pass-through model, pricing can be partly passed on to customers. (Lokesh Bhasin; Vinay Kumar Lohariwala)
Key Takeaway
Innova Captab delivered a strong Q1 FY27 with consolidated revenue of ₹470.9 crores, up 34% YoY, EBITDA of ₹75.1 crores (16% margin), and PAT of ₹44.1 crores, up 42% YoY - with volume growth of ~20-22% and Jammu contributing ₹107 crores at positive EBITDA of ₹1-1.5 crores. CDMO grew 32% to ₹328.7 crores and Branded Generics 39% to ₹142.2 crores, with exports at 32% of revenue. Management reaffirmed FY27 guidance of 20%+ volume growth with profitability outpacing revenue, maintaining a 15-16% ±2% EBITDA margin band while acknowledging a path to 17-18% as Jammu ramps to its ₹1,400 crores optimum revenue potential. Strategy centers on deepening customer relationships, expanding complex dosage capabilities, entering new therapeutic categories, and disciplined capital allocation with annual growth capex of ₹20-30 crores. Key watch points remain Jammu ramp-up execution through ROW approvals, business mix volatility, API price pass-through dynamics, and potential margin drag from future greenfield investments, with the Baddi expansion plan yet to be finalized.